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Intracellular protein-protein interactions are dynamic events requiring tightly regulated
spatial and temporal checkpoints. But how are these spatial and temporal cues
integrated to produce highly specific molecular response patterns? A helpful analogy to
this process is that of a cellular map, one based on the fleeting localization and activity
of various coordinating proteins that direct a wide array of interactions between key
molecules. One such protein, myristoylated alanine-rich C-kinase substrate (MARCKS)
has recently emerged as an important component of this cellular map, governing a
wide variety of protein interactions in every cell type within the brain. In addition to its
well-documented interactions with the actin cytoskeleton, MARCKS has been found to
interact with a number of other proteins involved in processes ranging from intracellular
signaling to process outgrowth. Here, we will explore these diverse interactions and their
role in an array of brain-specific functions that have important implications for many
neurological conditions.
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In the years since myristoylated alanine-rich C-kinase substrate (MARCKS) was first
identified as a primary target of protein kinase C (PKC; Wu et al., 1982), it has emerged
as an essential regulator of the dynamic actin cytoskeleton, membrane phosphoinositides,
and many highly localized molecular interactions, with diverse roles in a variety of cell
types, tissues, and organs. These roles have been heavily investigated in the brain, where
the modulation of these pathways is critical for fundamental processes such as neurite
outgrowth, endo and exocytosis, and synaptic plasticity. These varied functions have revealed
MARCKS as an integral player in a host of physiological processes and novel etiologies,
ranging from development of the cerebral cortex (Stumpo et al., 1995; Weimer et al., 2009)
to aging-associated cognitive decline (Trovò et al., 2013).
MARCKS is a 32 kDa protein with two functional domains that mediate interactions with
the plasma membrane (Figure 1). The N-terminus undergoes co-translational myristoylation,
the covalent addition of a hydrophobic myristoyl group. Interestingly, this modification has been
determined to be reversible, a phenomenon that is unique to MARCKS (Manenti et al., 1994).
The effector domain (ED) is strongly basic and contains multiple serine residues that can be
phosphorylated by PKC. In the unphosphorylated state, the ED has a net positive charge and
is attracted to negatively charged phospholipids in the inner leaflet of the plasma membrane.
This allows the N-terminal myristoyl group to reversibly insert into the plasma membrane,
facilitating a relatively stable membrane interaction. When the ED is phosphorylated, however,
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FIGURE 1 | MARCKS structure and the electrostatic switch
mechanism. (A) MARCKS contains three highly conserved domains: an
N-terminal myristoylation domain, the nearby MH2 domain of unknown
function, and the ED, which contains three serines that are phosphorylated by
PKC. (B) When the ED of MARCKS is unphosphorylated, positively charged
amino acid residues interact with negatively charged phospholipids in the
inner leaflet of the plasma membrane, and the N-terminal myristate inserts into
the plasma membrane. Phosphorylation by PKC or association with
Ca2+/calmodulin abolishes the affinity between the ED and the plasma
membrane, and MARCKS translocates to the cytosol.
the negatively charged phosphates reduce the affinity of the
ED for the membrane, and MARCKS translocates to the
cytosol (Kim et al., 1994a; McLaughlin and Aderem, 1995).
Calmodulin can also associate with the ED upon activation
by increased intracellular Ca2+ levels, similarly resulting
in translocation to the cytosol (Kim et al., 1994b). This
mechanism, wherein the dual interactions of the ED and
the myristoyl group are required for membrane localization,
has been called an ‘‘electrostatic switch’’ (McLaughlin and
Aderem, 1995; Figure 1B). While the phosphorylation or
calmodulin-mediated regulation of MARCKS localization is
generally accepted in the literature, it has not been definitively
demonstrated that individual MARCKS molecules repetitively
cycle between cytosolic and membrane localization in response
to phosphorylation and dephosphorylation. Single molecule
tracking studies may soon conclusively resolve this mechanism.
Furthermore, some evidence suggests that phosphorylated
MARCKS may translocate not only to the cytosol, but also the
nucleus, where its role is unclear (Topham et al., 1998; Michaut
et al., 2005).
PKC phosphorylation domains closely resembling the
MARCKS ED, often termed MARCKS-like domains, are also
found in a number of other proteins, some of which share
overlapping functions with MARCKS. Diacylglycerol kinase
zeta (DGKζ) is an important regulator of intracellular lipid
signaling, which MARCKS is also believed to influence. DGKζ
contains a MARCKS-like domain which facilitates its nuclear
localization following PKC phosphorylation (Topham et al.,
1998). Members of the adducin family of proteins also contain
MARCKS-like domains (Joshi et al., 1991; Dong et al., 1995),
are known to regulate actin and spectrin components of the
cytoskeleton, and are regulated by PKC. Src-Suppressed CKinase
Substrate (SseCKS), a cell-cycle regulated scaffolding protein
that interacts with membrane phospholipids and actin, contains
three MARCKS-like domains which are phosphorylated by
PKC (Ko et al., 2014). Another protein, aptly named MARCKS-
like protein 1, maintains particularly strong homology with
MARCKS, and appears to share some of its functions in CNS
development (Stumpo et al., 1998). This high homology is due
not only to an ED very similar to that of MARCKS, but also
an N-terminal consensus myristoylation sequence (Umekage
and Kato, 1991). As with the other proteins containing
MARCKS-like domains, however, MARCKS-like protein 1
has differences both in terms of expression pattern and amino
acid composition within and outside of the ED, resulting in
distinct functional roles (Umekage and Kato, 1991; Stumpo et al.,
1998).
PKC phosphorylates the MARCKS ED at three or four
serines, depending on the species. In mice, where these
interactions have been heavily studied, PKC phosphorylates
ED serines 152, 156, and 163 (Herget et al., 1995). In
addition to phosphorylation by PKC, the ED of human
MARCKS is also phosphorylated by Rho-kinase at serine 159
(Ikenoya et al., 2002). MARCKS also contains unique domains
outside of the ED, which are phosphorylated by proline-
directed kinases at serine and threonine residues. The kinases
responsible for non-ED phosphorylation include mitogen-
activated protein kinase 1 (MAPK1; Schonwasser et al., 1996),
cyclin-dependent kinase 1 (cdk1) and cyclin-dependent kinase
5 (cdk5; Yamamoto et al., 1995). While phosphorylation of
the ED by PKC inhibits calmodulin binding, phosphorylation
by cdk1 or cdk5 actually encourages it, suggesting a complex
regulatory network (Yamamoto et al., 1995). Recently, the
S25 residue within the relatively uncharacterized, but highly
conserved, MARCKS MH2 domain was demonstrated to be
phosphorylated by proline-directed kinases; primarily cdk5. This
domain is only phosphorylated in neurons, does not affect
association with membranes, and is yet to be functionally
characterized (Tinoco et al., 2014). Interestingly, MARCKS
has been demonstrated to cluster in groups with comparable
phosphorylation states at the mutually exclusive S25 and ED
residues (Toledo et al., 2013), perhaps due to the localization
patterns induced by these modifications. The functional
significance of phosphorylation outside of the ED requires
further investigation; presently the vast majority of what is
known regarding the regulation of MARCKS is in relation to
phosphorylation by PKC.
Likewise, relatively little is known about the
dephosphorylation of MARCKS, both within and outside
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of the ED. MARCKS is dephosphorylated, at least in part, by
protein phosphatase 2A (PP2A; Tanabe et al., 2012) at both
PKC and cdk1/5 residues (Yamamoto et al., 1995). Additionally,
some groups have shown that calcineurin can dephosphorylate
MARCKS PKC sites (Seki et al., 1995), although others have
concluded that it has no such activity (Yamamoto et al., 1995).
Since dephosphorylation has significant implications for the
function of MARCKS, through the modulation of localization
and affinity for various partners, more work is necessary in this
area in order to have a balanced understanding of MARCKS
regulation.
The phosphorylation-mediated regulation of membrane vs.
cytosolic MARCKS localization has proven to be functionally
critical. When MARCKS is localized to the membrane, the
ED facilitates crosslinking of filamentous actin through two
separate actin binding sites (Yarmola et al., 2001). This
activity is lost upon phosphorylation of the ED (Hartwig
et al., 1992), perhaps due to conformational changes induced
therein (Bubb et al., 1999; Figure 2A). Thus, MARCKS is
capable of transducing signals from intra- or extracellular
sources, through PKC, to the actin cytoskeleton. Similarly,
membrane-associated MARCKS has been shown to interact
with phosphatidylinositol 4,5-bisphosphate (PIP2; Sundaram
et al., 2004), potentially sequestering it and regulating its
availability for phospholipase C (PLC) and phosphoinositide
3-kinase (PI3K), thereby regulating downstream signaling
molecules such as phosphatidylinositol 3,4,5-trisphosphate
(PIP3), diacylglycerol (DAG), and Akt (Figure 2B). This activity
suggests that MARCKS could modulate sustained intracellular
signaling cascades following translocation. Furthermore,
MARCKS may restrict the localization of various signaling
molecules and complexes, influencing cell polarity and
regulating domain-specific functions (Weimer et al., 2009).
In mature neurons, for example, MARCKS concentrates PIP2
in the postsynaptic compartment, ensuring its availability for
participation in postsynaptic signaling cascades (Trovò et al.,
2013).
As a result of its interactions with such integral structural
and signaling proteins, MARCKS has been demonstrated to
be involved in myriad cellular processes. In the brain, where
dynamic regulation of the actin cytoskeleton plays a central role
in neuronal function, MARCKS has demonstrated involvement
in neural development, physiology, and neurodegeneration. This
review will highlight recent advances in understanding the role of
MARCKS in the brain, and will propose potential areas for future
exploitation both as a window into neuronal physiology and as a
therapeutic target in a variety of nervous system disorders.
MARCKS IN BRAIN DEVELOPMENT
MARCKS is expressed at the highest levels in the brain during
embryonic development (Stumpo et al., 1995), and ubiquitous
expression persists throughout adulthood (Zhang et al., 2014).
Distinct subcellular localization patterns are evident in different
cell types. In neurons, MARCKS is heterogeneously distributed
and enriched in axons and dendrites (Ouimet et al., 1990;
Calabrese and Halpain, 2005). Different cell populations within
FIGURE 2 | Molecular Interactions and Cellular Roles of MARCKS.
(A) The MARCKS ED crosslinks actin filaments (green) at the plasma
membrane, but this activity is reduced upon PKC phosphorylation or
Ca2+/calmodulin binding and subsequent translocation. This is believed to
facilitate morphological changes at the membrane. (B) MARCKS can
concentrate signaling molecules such as PIP2 within specific membrane
microdomains. Upon MARCKS translocation, these molecules are then made
available for signal transduction. The influence of MARCKS on the PLCγ
catalyzed production of inositol trisphosphate (IP3) and diacylglycerol (DAG)
from PIP2 is one such example. In the synapse, this modulation of signal
transduction is hypothesized to contribute to the role of MARCKS in learning
and memory. (C) MARCKS interacts with PSA modified proteins, such as
neural cell adhesion molecule (NCAM, green) within the plane of the plasma
membrane, facilitating cell-cell interactions at the synapse and elsewhere.
(D) MARCKS facilitates the docking and fusion of Rab10 (blue) -positive
vesicles, which are hypothesized to supply the membrane necessary for
process outgrowth.
the brain can also have widely varying expression levels; for
example, MARCKS expression is robust in the hippocampal
mossy fiber pathway, but not in the Schaffer collaterals (Hussain
et al., 2006). During early development, MARCKS is broadly
expressed in the cells surrounding the neural tube (Blackshear
et al., 1996), and later, throughout the forebrain with particular
enrichment at the apical membranes of ventricular zone neural
progenitor cells (NPCs; Weimer et al., 2009).
Studies with Marcks knockout mice (Marcks−/−) have
demonstrated that MARCKS is crucial for normal brain
development. It has long been known that knockout is
embryonically lethal, resulting in gross anatomical defects
including exencephaly, lamination abnormalities, and absence of
forebrain commissures (Stumpo et al., 1995). More recent
investigations have begun to elucidate the cellular and
molecular mechanisms underlying these defects, identifying
putative functions for MARCKS in NPC proliferation, neuronal
migration, and neurite outgrowth (Shiraishi et al., 2006; Weimer
et al., 2009; Tanabe et al., 2012; Theis et al., 2013). Interestingly,
these defects can be rescued both by mutant MARCKS lacking
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PKC phosphorylation sites (Scarlett and Blackshear, 2003), as
well as mutant nonmyristoylatable MARCKS (Swierczynski
et al., 1996).
Radial glia, which serve both as NPCs as well as a migratory
scaffold for migrating neurons in the developing cortex, are
displaced in Marcks−/− embryos (Weimer et al., 2009). Radial
glia typically reside adjacent to the lateral ventricles, with apical
processes in the ventricular wall and basal processes extending
through the cortical plate to the pial surface. The endfeet
of both of these processes are concentrated with MARCKS,
and it has been proposed that MARCKS serves to anchor
cell polarity complexes, such as the PAR polarity complex of
PAR3, PAR6, and aPKCζ, at these locations (Weimer et al.,
2009). Without MARCKS, radial progenitors lose their apical
attachments and become aberrantly displaced away from the
ventricular zone, and do not develop appropriately oriented
basal processes, rendering the migratory scaffold disorganized.
Without a properly structured scaffold, clearly delineated cortical
layers are lost, resulting in abundant heterotopias (Stumpo
et al., 1995; Weimer et al., 2009). Retinal lamination, which is
also dependent on a form of radial glia, is also defective in
Marcks−/− embryos (Stumpo et al., 1995). Rescue experiments
with mutant MARCKS mice lacking either an N-terminal
glycine or phosphorylatable serine residues in the ED (Stumpo
et al., 1995; Swierczynski et al., 1996; Scarlett and Blackshear,
2003) have suggested that the role of MARCKS in neuronal
progenitor positioning depends on myristoylation rather than
phosphorylation (Weimer et al., 2009), although the specific
molecular interactions underlying the functions of MARCKS in
the developing cortex remain to be characterized.
It is possible that MARCKS is also influencing signaling
pathways that are important for progenitor identity and
differentiation. MARCKS has been shown to mediate PKC-
driven modulation of ErbB2 signaling (Jin Cho et al.,
2001), which is essential for maintaining radial glial identity
(Ghashghaei et al., 2007). MARCKS has also recently been shown
to interact with polysialic acid (PSA; Theis et al., 2013). PSA
is added posttranslationally to neural cell adhesion molecule
(NCAM), and has been implicated in NPC differentiation and
migration (Angata et al., 2007), and axon outgrowth (Zhang
et al., 1992). When intracellular MARCKS and extracellular PSA
both invade the plasmamembrane, they have been demonstrated
to colocalize in a functional interaction in the plane of the
membrane that stimulates neurite outgrowth (Theis et al., 2013;
Figure 2C). Given the necessity of PSA for proper axonal
commissure formation (Marx et al., 2001; Langhauser et al.,
2012), these results may also hint at a molecular mechanism
underlying the commissure defects observed in MARCKS
knockout mice (Stumpo et al., 1995). It is also possible, however,
that the defective migration patterns observed in the absence
of MARCKS place newly differentiated neurons outside of their
appropriate micro-niche, rendering them incapable of correctly
directing axons.
Still other pathways could be responsible for the necessity of
MARCKS in axon outgrowth. MARCKS has been demonstrated
to interact in a phosphorylation state-dependent manner with
Rab10, a small GTPase associated with plasmalemmal precursor
vesicles. When the ED is in the unphosphorylated state,
MARCKS mediates docking and fusion of Rab10 vesicles, which
supply axons with membrane necessary for growth (Xu et al.,
2014; Figure 2D). In other studies, MARCKS has also been
shown to promote neurite outgrowth when dephosphorylated
in response to IGF-1 stimulation (Shiraishi et al., 2006),
or when phosphorylation is blocked (Gatlin et al., 2006).
Taken together, these results suggest that axon outgrowth is
regulated, in part, through phosphorylation/dephosphorylation
of the MARCKS ED, which modulates Rab10 vesicle fusion
in growth cones. This potentially contributes both to the
lack of forebrain commissures and to the aberrant radial
scaffold navigation observed in Marcks−/− embryos. It remains
to be seen precisely how MARCKS influences neuronal
migration.
MARCKS IN THE DYNAMIC SYNAPSE
In the mature brain, MARCKS is enriched both within axon
terminals and dendritic spines. Through interactions with actin,
PIP2, and various signaling proteins, it has been proposed
to influence synaptic signaling both pre- and postsynaptically.
In presynaptic terminals, MARCKS interacts with synapsin I
(Mizutani et al., 1992), colocalizes with synaptic vesicles (Ouimet
et al., 1990), and is phosphorylated by PKC (Coffey et al., 1994;
Obis et al., 2015). It remains to be seen, however, whether
these interactions have any effect on neurotransmitter vesicle
positioning or release. Thus far, electrophysiological studies have
found no evidence of altered presynaptic dynamics inMarcks−/−
neurons (McNamara et al., 2005; Hussain et al., 2006). An
alternative presynaptic role for MARCKS involves synapse
formation and maintenance. MARCKS could aid in presynaptic
growth and branching necessary for synapse formation through
interactions with postsynaptic cells expressing PSA-modified
proteins (Theis et al., 2013) or by modulating Rab10 vesicle
localization (Xu et al., 2014): processes that have been implicated
in synaptic plasticity (Muller et al., 1996; Glodowski et al.,
2007). Similarly, MARCKS may be important for synaptic
terminal retraction; synapses have been observed to degenerate
inMarcks−/− neurons, but the presynaptic terminals often fail to
withdraw, and there is an increase in the number of terminals
without a postsynaptic partner (Calabrese and Halpain, 2005).
More work will be required to resolve the presynaptic effects of
MARCKS.
Postsynaptic functions for MARCKS are much more
firmly established. In terms of gross morphology,
MARCKS overexpression causes profound changes in
dendritic arborization (Calabrese and Halpain, 2005), and
hyperphosphorylation of MARCKS by PKC has been correlated
with reduced dendritic complexity (Garrett et al., 2012).
These studies draw interesting parallels with those of other
groups, who have shown that MARCKS mediates lamellipodia
formation and neurite outgrowth in neuroblastoma cells
(Tanabe et al., 2012), axon outgrowth in cortical neurons (Xu
et al., 2014) and basal process branching in radial glia (Weimer
et al., 2009). The most parsimonious explanation for these
phenomena is that MARCKS is an important regulator of the
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fundamental actin-dependent processes required for cellular
outgrowth culminating in a variety of structures. One such
structure, dendritic spines, are strongly influenced by MARCKS;
Knockdown or expression of a mutant form of MARCKS
that mimics constitutive phosphorylation results in decreased
spine number, size, and width, and over expression results in
spine elongation and fusion (Calabrese and Halpain, 2005).
These changes appear to be largely influenced by MARCKS-
mediated translocation of f-actin. When phosphorylated,
MARCKS translocates from the inner membrane surface,
reducing levels of f-actin within spines, causing some to retract
or fuse with neighboring spines, and others to exhibit immature
filopodia-like morphology (Calabrese and Halpain, 2005).
Since synapse stability and strength are largely influenced
by dendritic spine morphology, with wide, bulbous spines
promoting persistent synapses, these morphological changes,
as well as the reduction in spine numbers, suggest that altered
levels of postsynaptic membrane-associated MARCKS may
cause synapse destabilization. These changes are of functional
consequence. Reduced MARCKS levels have been shown to
inhibit long-term potentiation (LTP) and spatial learning in
mice, without affecting basal synaptic transmission (McNamara
et al., 2005; Hussain et al., 2006). Unique patterns of MARCKS
translocation have also been observed after imprinting training
in chicks. In this paradigm, chicks are trained to recognize
(and prefer) a unique moving object shortly after hatching,
taking advantage of the critical window when chicks will
‘‘imprint’’ on the first moving object they see. Twenty four
hours after training, membrane-associated MARCKS increases
in the intermediate medial mesopallidum, where imprinting
memories are stored (Solomonia et al., 2008). It is plausible
that, during training, increases in postsynaptic calcium in
learning-specific circuits activate calmodulin, which binds
the ED of MARCKS resulting in its translocation to the
cytosol, allowing for structural changes to take place at the
membrane. Once these changes have taken place, increasing
membrane-associated MARCKS then stabilizes the new spine
configurations (Solomonia et al., 2008). This is a tempting
hypothesis, and will require further investigation into MARCKS
translocation patterns in memory acquisition, consolidation,
and extinction, in which new associative memories supersede
old ones.
Besides phosphorylation and calmodulin binding, what
else could be regulating MARCKS at the synapse? MARCKS
has been shown to be selectively degraded by cathepsin-B
after intense stimulation of N-methyl-D-aspartate (NMDA)
receptors, resulting in dendritic spine collapse (Graber et al.,
2004). Following brief ischemic insults, postsynaptic MARCKS
can also be ubiquitinated, resulting in a brief and reversible
form of dendritic spine collapse that is believed to be protective
against NMDA receptor-mediated toxicity (Meller et al.,
2008). These results demonstrate the complex manner in
which MARCKS is posttranslationally regulated. MARCKS
can be phosphorylated within or outside of the ED, cleaved
by cathepsin-B, myristoylated and demyristoylated, and
ubiquitinated, all presumably modifying the ability of MARCKS
to crosslink actin filaments, and regulating membrane and
cytoskeleton plasticity in dynamic locations such as dendritic
spines.
MARCKS has also been shown to influence synaptic plasticity
through modulation of PIP2 availability. In aging mice, synaptic
levels of membrane MARCKS have been shown to decline
concurrently with PIP2 levels and PLCγ activity, and in
culture, MARCKS overexpression is sufficient to restore synaptic
PIP2 and PLCγ (Trovò et al., 2013). Intriguingly, MARCKS
overexpression in vivo completely rescues age-related deficits in
LTP and memory retention (Trovò et al., 2013). The authors
of this study suggest that MARCKS must be sequestering PIP2
at specific sites in the membrane, such as dendritic spines, and
then releasing it at appropriate times to allow for PIP2-related
signaling cascades. Furthermore, their results suggest that an
abundance of postsynapticMARCKS appears to promote healthy
synaptic PIP2 and PLCγ levels throughout life, maintaining some
of the signaling cascades important for learning and memory.
This activity complements the putative role of MARCKS in
directly crosslinking actin within spines, as PIP2 itself is known
as an important regulator of the actin cytoskeleton.
MARCKS IN NON-NEURONAL CELLS
WITHIN THE BRAIN
The diverse roles of actin and signaling molecules like
PIP2 are not limited to synapses or neurons, and as such,
MARCKS has many functions in other cell types within the
brain. PKC signaling underlies some types of blood-retinal
barrier breakdown (Titchenell et al., 2012), and MARCKS has
been shown to regulate endothelial cell permeability through
modification of the actin cytoskeleton (Jin et al., 2012), hinting
at a possible role for MARCKS in blood-brain barrier (BBB)
dynamics. Similarly, MARCKS appears to be important in
ependymal cells, which form the interface between cerebrospinal
fluid and the brain interstitium. A recent study demonstrated
an exciting novel role for MARCKS in the aging brain;
membrane associated MARCKS declines with age in ependymal
cells, concomitant with decreasing function in mucin clearance
and barrier functions (Muthusamy et al., 2015). In these
cells, MARCKS influences the localization of protein chloride
channel calcium-activated family member 3 (Clca3), which
decorates mucin granules. Interestingly, healthy ependymal cells
concentrate MARCKS at their apical membranes (Muthusamy
et al., 2015), similar to the localization pattern observed in
the radial glia that line the ventricles during development
(Weimer et al., 2009). This apical clustering is lost, however,
with advanced age in mice, resulting in the observed deficits.
When MARCKS is conditionally-deleted in ependymal cells,
ependymal barrier function is similarly hindered, leading to the
aberrant activation of astrocytes and microglia in the forebrain
interstitium (Muthusamy et al., 2015). These results underscore
the possible involvement of MARCKS in a variety of aging-
related etiologies.
MARCKS also has roles in glial cells themselves. In microglia,
MARCKS mRNA and protein are upregulated in response to
lipopolysaccharide (LPS; Sunohara et al., 2001) or amyloid-β (Aβ;
Hasegawa et al., 2001; Murphy et al., 2003) administration, and
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kainic acid-induced seizures (Eun et al., 2006): all treatments
that result in microglial activation. In astrocytes, MARCKS has
been shown to participate in a pathway that regulates migration
and morphological changes resembling reactive gliosis (Lee
et al., 2012). MARCKS has also been shown to regulate the
differentiation of oligodendrocytes in a process that involves
both reorganization of actin networks and the polarization of
trafficking cues (Baron et al., 1999). These findings demonstrate
the ubiquitous importance of MARCKS in the brain, and support
a need for further research examining the functions of MARCKS
in endothelial and various glial cells.
MARCKS IN NEUROLOGICAL DISORDERS
Given its critical roles in a variety of brain cell types, it is not
surprising that MARCKS has been the subject of intense research
into the etiology and treatment of various neurological disorders.
Results thus far have been encouraging, identifying MARCKS as
an important player in numerous disorders involving synaptic
abnormalities and neurodegeneration (Lenox and Wang, 2003;
Kim et al., 2010; Yamamoto et al., 2014; Tagawa et al., 2015;
Trovò et al., 2015), and investigation is underway to identify
treatments that will effectively modulate MARCKS activity to
restore physiological functions (Singer et al., 2004).
There are multiple ways in which MARCKS levels could
be modulated in human disease, including through gene
polymorphisms. It is unknown how widespread MARCKS
polymorphisms are in humans. Results with animal models
suggest that loss of function mutations would be embryonically
lethal in the homozygous condition (Stumpo et al., 1995),
although this has never been confirmed in human patients.
Heterozygotes, however, would be much more likely to survive
and may possess some of the deficiencies observed inMarcks+/−
mice, such as impaired LTP and spatial learning (McNamara
et al., 1998; Hussain et al., 2006). The prevalence of MARCKS
mutations in humans and associations with diseases including
learning disorders warrants further attention.
Even in the absence ofMARCKSmutations, alteredMARCKS
activity has been found to be part of the core etiology in some
genetic conditions. Niemann-Pick disease type A (NPDA), a
fatal lysosomal storage disorder caused by mutations in the
acid sphingomyelinase gene, results in the accumulation of
sphingomyelin in lysosomes and the plasma membrane which,
in turn, leads to reduced synaptic levels of MARCKS and
PIP2, and synaptic deficits. Intracerebroventricular infusion of
recombinant MARCKS ED restores PIP2 levels and improves
behavioral parameters in mouse models of NPDA (Trovò et al.,
2015). Another condition, spinocerebellar ataxia type 14 (SA), is
caused by mutations in PKCγ. Cell culture studies have shown
that the mutant PKCγ inhibits synaptogenesis and dendrite
development (Seki et al., 2009). The investigators who performed
this work hypothesized that a deficit in macropinocytosis, a
process in which endocytosis is used to traffic membranes,
underlies these problems, and have demonstrated that MARCKS
may be the relevant PKCγ substrate dysregulated in the disease
state (Yamamoto et al., 2014). Going beyond SA, these findings
support a general role for MARCKS in endocytosis, which is not
surprising, considering theMARCKS ED has been shown to have
membrane curvature sensing capability (Morton et al., 2014).
Intriguingly, Other authors have suggested that MARCKS-
mediated endocytosis deficits could contribute to amyloid beta
aggregation in Alzheimer’s disease (AD; Su et al., 2010).
Additionally, altered MARCKS levels have been implicated
in a number of mental disorders, and have been observed
in schizophrenia (Pinner et al., 2014) and depression (Redei
et al., 2014) patients, as well as violent suicide completers
(Punzi et al., 2014). It is unclear, however, if these observations
represent transcriptional, translational, or other aberrations.
Surprisingly, it is possible that MARCKS has unknowingly been
targeted for decades in the treatment of psychiatric disorders.
One study demonstrates that electroconvulsive therapy (ECT)
increases phosphorylation of MARCKS in the time period
immediately following treatment, potentially facilitating the
long-term synaptic changes that make ECT effective (Kim
et al., 2010). MARCKS is also responsive to lithium treatment.
Chronic lithium administration acts as a repressor at the
MARCKS promoter, decreasing brain mRNA and protein levels
by 50%, and has been proposed to be, at least partially,
responsible for the efficacy of lithium treatment in bipolar
disorder (Lenox and Wang, 2003). Interestingly, lithium also
has some demonstrated efficacy in neurodegenerative disorders
where MARCKS involvement has been proposed, namely
Parkinson’s disease (PD; Kim et al., 2011; Lieu et al., 2014)
and AD (Appleby and Cummings, 2013; Sofola-Adesakin et al.,
2014).
A microarray study identified MARCKS as one of four
neurotransmission-related genes differentially expressed in PD
(Rakshit et al., 2014). Likewise, a recent study found a
strong association between MARCKS phosphorylation and AD
pathology in both humans and mice, and determined that
hyperphosphorylation of MARCKS was the primary factor in the
initiation of AD synapse pathology. Remarkably, the same study
found that shRNA-mediated knockdown of MARCKS was able
to rescue decreased spine density in cortical neurons in a mouse
model of AD (Tagawa et al., 2015). This is a surprising result,
considering that the hyperphosphorylation observed in AD
would be expected to reduce the amount of MARCKS available at
the membrane for actin crosslinking and PIP2 sequestration. The
authors were working under the unconventional hypothesis that
phosphorylated MARCKS actively inhibits actin crosslinking,
rather than unphosphorylated MARCKS facilitating it. Within
this model, MARCKS knockdown could allow polymerized actin
to stabilize dendritic spines, leading to the observed outcomes.
Still, these results are in direct contrast with those of other
authors, including Calabrese and Halpain (2005) who found that
MARCKS knockdown reduces spine density. These conflicting
results will require resolution with more studies.
Nevertheless, the work of Tagawa et al. provides convincing
evidence for the presence of MARCKS etiology in AD, an
idea which is supported by the work of several groups.
Phosphorylated MARCKS has been observed within dystrophic
neurites and senile plaques in the brains of human AD patients
(Kimura et al., 2000). Aβ, the main component of senile
plaques and the putative toxic species underlying AD pathology,
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causes MARCKS phosphorylation through PKC and MAPK,
as well as MARCKS upregulation, when applied exogenously
in cultured neurons and microglia (Hasegawa et al., 2001;
Tanimukai et al., 2002; Murphy et al., 2003). MARCKS has
also been implicated in the secretion of apolipoprotein E (apoE;
Karunakaran et al., 2013), a cholesterol transporting molecule
with certain polymorphisms strongly associated with AD.
The associations with AD and roles in dendritic spine
maintenance also suggest possible roles for MARCKS in Down
syndrome (DS). DS, caused by trisomy of chromosome 21, is
frequently comorbid with AD. Neocortical lamination defects
and dendritic spine abnormalities have been observed in human
DS patients (Kaufmann and Moser, 2000, in review), and
reductions in dendritic spines are more severe when DS and
AD are comorbid (Ferrer and Gullotta, 1990). These features
resemble some of those seen in studies where MARCKS levels
and activity are altered (Calabrese and Halpain, 2005; Weimer
et al., 2009). The gene for amyloid precursor protein (APP)
is located on chromosome 21, which has been proposed to
explain the high prevalence of AD in DS patients. Interestingly,
a MARCKS pseudogene, MARCKSP1, is located adjacent to
and approximately 56 kilobases upstream from, the APP gene.
When MARCKS was first mapped to chromosome 6, it was
observed that MARCKS mRNA hybridized strongly to a location
on chromosome 21 (Sakai et al., 1992); presumably this was
the MARCKS pseudogene. Could the expression of MARCKS
and APP be linked through this pseudogene? It is unknown
if MARCKSP1 is transcribed, but, if it is, it is possible that
its transcription could be coregulated with that of APP due
to proximity and shared cis-acting elements. Interestingly,
MARCKSP1 contains a microRNA-21 targeting site identical
to one found in the 3’ untranslated region of MARCKS. Since
microRNA-21 has been shown to regulate MARCKS (Li et al.,
2009), if a MARCKSP1 transcript were produced it could
potentially act as a microRNA sponge to influence MARCKS
expression. While only speculative, such a scenario could have
important implications for AD and DS. Future studies should
investigate genetic interactions such as these, as well as potential
roles for MARCKS in DS and other cognitive disorders involving
dendritic spine pathology.
Likewise, MARCKS etiology and potential as a treatment
target should be explored in other neurodegenerative diseases,
such as amyotrophic lateral sclerosis (ALS) and Huntington’s
disease, where dendritic spine loss has been observed to
preclude neurodegeneration. To date, no studies have been
published examining the role of MARCKS in these disorders.
MARCKS also has demonstrated involvement in a number of
other conditions where it has not been adequately investigated,
including neuropathic pain (Tatsumi et al., 2005), seizure
disorders (Graber et al., 2004; Eun et al., 2006), gliomas (Jarboe
et al., 2012), and methyl mercury poisoning (Shiraishi et al.,
2014).
FUTURE DIRECTIONS
The last three decades have seen great progress towards
understanding the structure, regulation, and functions
of MARCKS. Much remains unknown, however. At the
fundamental level, the nature of the interactions between
MARCKS and its various protein partners, such as actin and
PKC, are still somewhat unclear. Much evidence supports the
notion that MARCKS influences the actin cytoskeleton, but the
molecular details of this interaction, such as specific binding
sites and responsivity to specific phosphorylation patterns,
require some clarification. Similarly, while MARCKS is a well-
established substrate for PKC, this function appears to go beyond
a simple kinase-substrate relationship (Yamamoto et al., 2014),
with the two proteins actively influencing the localization of one
another and thus, their availability for other partners. A better
understanding of these processes should help reconcile some
of the conflicting results that have been obtained to date, and
provide insight into other cellular roles for MARCKS.
There is strong evidence that MARKS has different functions
in different cell types and at different times in development
(Solomonia et al., 2008; Weimer et al., 2009; Trovò et al.,
2013; Muthusamy et al., 2015). These variable functions could
be largely mediated through subcellular localization patterns
of MARCKS, but also through its ability to dock and bind
different partners. Characterizing these variable functions, as
well as the specific interactions that facilitate them, remains an
important goal. Studies using conditional and inducible genetic
manipulations targeting MARCKS will enable great progress
in dissecting these functions and pathways. Likewise, animal
models such as the newly described floxed Marcks mouse
(Muthusamy et al., 2015), will allow the effects of MARCKS
knockout to be studied in vivo in discrete cell types through
time points beyond birth, circumventing the lethality of complete
knockout.
Even within specific cell populations, it appears likely that
MARCKS could have a multitude of roles. While the functions of
MARCKS have been most extensively studied in cell periphery,
in relation to cytoskeletal and phosphoinositide dynamics,
MARCKS has also frequently been observed in the perinuclear
region (Techasen et al., 2010; Yamamoto et al., 2014), where
its function is not well understood, and even in the nucleus
itself, in the case of oocytes (Michaut et al., 2005). While nuclear
localization has not been reported in other cell types, it may be
expected to occur to some extent, given the presence of a nuclear
localization signal within the ED (Topham et al., 1998). What
could MARCKS be doing in the nucleus? Future studies should
examine possible roles in nuclear phosphoinositide signaling,
nuclear actin modulation, and even potential transcription factor
activity.
Within all localizations, the regulation of MARCKS activity
also requires further investigation. Phosphorylation by PKC
has been relatively well characterized, but the influence of
other kinases that phosphorylate MARCKS both within and
outside of the ED should be explored. Non-kinase regulatory
mechanisms such as myristoylation/demyristoylation cycles and
ubiquitination have only begun to be investigated, as have
mechanisms regulating transcription and mRNA stability. For
example, micro-RNA 21 has been shown to target MARCKS
(Li et al., 2009), and a long noncoding RNA transcribed from
a region adjacent to MARCKS has been shown to influence
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methylation ofMARCKS and is upregulated in certain conditions
(Punzi et al., 2014), but interactions like this one are not well
understood. Similarly, while the MARCKS promoter contains a
number of transcription factor binding sites (Wang et al., 2002),
the significance of these interactions has not been elucidated.
Functionally, MARCKS is proving to have important
implications in a variety of conditions. In addition to various
neurodegenerative and cognitive disorders, several studies have
recently demonstrated that the declining MARCKS levels that
occur with age may underlie some forms of aging-related
pathology. Although this review focused only on brain-related
functions and disorders, MARCKS is also the subject of intense
investigation in other organ systems, and this work has already
resulted in promising therapies for some conditions (Singer
et al., 2004). In the coming years, improved knowledge of
MARCKS function has great potential to generate better models
of basic physiological and pathological processes, as well as novel
therapies.
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